Premium
Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results
Author(s) -
GREENBLATT DAVID J.,
COMER WALTER H.,
ELLIOTT HENRY W.,
SHADER RICHARD I.,
KNOWLES JOHN A.,
RUELIUS HANS W.
Publication year - 1977
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1977.tb05641.x
Subject(s) - clinical pharmacology , general hospital , medicine , mental health , library science , gerontology , family medicine , pharmacology , psychiatry , computer science
Four healthy male volunteers received 5 mg lorazepam as a single intravenous injection. Concentrations of lorazepam and its glucuronide metabolite were determined in multiple venous blood samples drawn during the 48 hours after dosing and in all urine collected during 96 hours after the dose. Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min. Lorazepam glucuronide, the major metabolic product of lorazepam, promptly appeared in blood, reached peak levels within 6 hours of the dose, then declined in parallel with the parent compound. A mean of 69 per cent of the dose was recovered in urine as lorazepam glucuronide.